RAZUMNA

Nootropics · Guide

Noopept (Omberacetam): The Subtle One You Run Daily

No jolt, no crash, nothing obvious on day one. The effect on recall and verbal fluency is cumulative. If you want to feel something immediately, this is the wrong compound alone.

Razumna editorial · 6 min read · Updated June 2026

The short answer

Noopept (Omberacetam) is a prodrug that converts to cycloprolylglycine, a dipeptide already present in the brain, which positively modulates AMPA receptors and is associated with raised BDNF and NGF in the hippocampus. It is subtle and non-stimulating. The reported effect on recall and verbal fluency builds over days rather than landing acutely, which is why it is run daily and usually paired with a choline source.

How it works

Omberacetam is a prodrug. Once absorbed it converts to cycloprolylglycine, an endogenous dipeptide, which behaves as a positive modulator of AMPA receptors and is associated with raised expression of BDNF and NGF in the hippocampus (Ostrovskaya et al., 2008). The parent compound clears in minutes while the reported effect outlasts it, which is the clue that it works through downstream neurotrophic signaling rather than an acute hit.

Dosing

The standard range is 10 to 30mg per day, typically split into 2 doses, taken in the morning and early afternoon. Start at 10mg and assess over several days; the dose-response is reported as flat across this range, so more is not reliably better. Onset is fast at 15 to 20 minutes, but the effect is cumulative over days. Sublingual dosing is sometimes used for faster onset given the low oral bioavailability.

Why pair it with choline

Like the racetams it resembles, noopept commonly requires a choline source such as CDP-choline or alpha-GPC to avoid a mild headache. Most users run it as a background layer under a primary wakefulness compound such as modafinil rather than as a stimulant replacement. For the acute-versus-cumulative tradeoff against a stimulating racetam, see Phenylpiracetam vs Noopept, and the stacking logic is in the racetam and choline guide.

The honest limits

The mechanism is well characterized and the neuroprotective data in animal models is solid, but human efficacy trials are few and short, and most involved people with a condition rather than healthy users. Long-term safety in healthy users has not been studied. It is sourced through a licensed CIS pharmacy network as a research and personal-use compound. This is information, not medical advice.

Common questions

Will I feel it like a stimulant?

No. It is subtle and non-stimulating, with no jolt and no crash. Users describe sharper recall and verbal fluency that builds over days. If you want an obvious lift, this is the wrong compound on its own.

Is there real human evidence?

The mechanism is well characterized and the animal neuroprotective data is solid. Human efficacy trials are few, short, and mostly in clinical populations. We do not present it as proven in healthy adults.

Do I need to take choline with it?

Most users do, to avoid a mild headache. CDP-choline or alpha-GPC are the common pairings.

Sources

This article is information, not medical advice. Razumna does not name compounds as treatments for any condition.